Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week Phase 2 open-label long-term safety study of emraclidine in adults with schizophrenia
2022-001151-16Phase 2Active
- Sponsor
- Cerevel Therapeutics
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emraclidine in schizophrenia, sponsored by Cerevel Therapeutics. Primary endpoint: Treatment-emergent adverse events. Started Aug 2022; status: active.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2022-001151-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001151-16.